Member's Email | Search | Sitemap | Contact us
    • Overview
    • Vision & Values
    • Letters from the Chairman & MD
    • Businesses
    • Evolution
    • Board of Directors
    • Corporate Citizenship
    • Awards & Recognitions
    • Global Locations
    • Markets
      • Overview
      • India
        • Overview
        • Divisions
        • Strategic Focus
      • Africa & Middle East
      • Asia
      • Russia & CIS
      • Latin America
      • Central Eastern Europe
    • Manufacturing
      Facilities
      • Overview
      • Nasik – India
      • Baddi – India
      • Nalagarh – India
      • Vysoke Myto – Czech
      • Sao Paulo – Brazil
    • Overview
    • New Chemical Entity
      (NCE)
      • Inflammation
      • Pain
      • Gastro Intestinal
    • New Biologics Entity
      (NBE)
      • Inflammation
      • Oncology
    • Research Pipeline
    • R&D Centres of
      Excellence
      • Overview
      • Mahape
      • Switzerland
      • Oxford
      • Sinnar
    • Scientific Advisory Board
    • Contacts
    • Financial Results / MD&A
    • Analyst Presentations
    • Annual Report
    • Shareholders Corner
      • Dividend History
      • Shareholder Forms/Queries
      • Shareholding Pattern
      • Corporate Governance Reports
    • Code of Conduct
    • FAQs
    • Careers Home
      • Overview
      • Awards and Recognitions
      • Values
    • Why Glenmark
      • Reasons to join Glenmark
      • Glenmark Centre of Learning
      • Employee Testimonials
      • Campus Recruitment
    • Apply
      • Current Jobs
      • For Consultants
      • Apply Online
      • FAQs
    • News Releases
    • Media Library
      • Profiles
      • Photo Gallery
      • Fact Sheet

  • Investors

    Annual Report FY 2010 - 11

    Q4 Financial results

    Investor Presentation- JP Morgan Healthcare conference, SFO, US

    Quick Links

    Global Presence

    NCE Pipeline

    India Formulations

    Careers

    Other Glenmark Websites

  • News

    09 May 2012
    Glenmark’s consolidated revenue increased by 36% in FY 11-12
    07 May 2012
    Glenmark Generics receives U.S. FDA approval for Lamotrigine Tablets
    09 Apr 2012
    Glenmark Generics receives ANDA approval for Norgestimate and Ethinyl Estradiol Tablets USP, 0.25 mg/0.035 mg
  • Glenmark has four R&D Centres of Excellence           

     

     

  • Glenmark Philosophy
    Video

    A new way for a
    new world

     

    homeflashslug

Home  |  About Glenmark  |  Formulations Business  |  Drugs Discovery |  Investors  |  Careers  |  Newsroom  |  Contact us

Copyright © 2009 Glenmark. All rights reserved